Patents by Inventor Yuji Kawamata
Yuji Kawamata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7625887Abstract: It is intended to provide a TGR5 receptor agonist containing a fused ring compound represented by the following general formula, its salt or a prodrug thereof: (1) wherein ring A represents an optionally substituted aromatic ring; and the ring B? represents a 5- to 8-membered ring having one or more substituents; which is useful in treating various diseases.Type: GrantFiled: January 27, 2004Date of Patent: December 1, 2009Assignee: Takeda Pharmaceutical Company LimitedInventors: Fumio Itoh, Shuji Hinuma, Naoyuki Kanzaki, Yuji Kawamata, Taisuke Tawaraishi, Yuji Ishichi, Mariko Hirohashi
-
Patent number: 7354726Abstract: The present invention intends to provide a screening of agonist/antagonist and the like. Specifically, the invention provides a method of screening a compound or its salt that alters the binding property between a novel G protein-coupled receptor protein or its salt, and a substance relating to cholesterol metabolism, which comprises using the receptor protein or its salt, which contains the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 14 or SEQ ID NO: 16, and the substance relating to cholesterol metabolism.Type: GrantFiled: April 11, 2002Date of Patent: April 8, 2008Assignee: Takeda Pharmaceutical Company LimitedInventors: Syuji Hinuma, Ryo Fujii, Yuji Kawamata, Masanori Miwa, Masaki Hosoya
-
Patent number: 7214495Abstract: By using (1) a G protein-coupled receptor protein having the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or its salt and (2) a fatty acid or an eicosanoid, a compound or its salt that can change the binding properties of the receptor protein or its salt to the fatty acid or the eicosanoid can be screened efficiently.Type: GrantFiled: February 13, 2003Date of Patent: May 8, 2007Assignee: Takeda Pharmaceutical Company LimitedInventors: Shuji Hinuma, Masaki Hosoya, Yasuaki Ito, Makoto Kobayashi, Hideyuki Tanaka, Shoichi Ohkubo, Ryo Fujii, Hideki Kizawa, Yuji Kawamata, Kazuhiro Ogi, Masataka Harada
-
Publication number: 20060199795Abstract: The present invention provides a TGR5 receptor agonist comprising a fused ring compound represented by the formula wherein ring A is an optionally substituted aromatic ring; and ring B? is a 5- to 8-membered ring having one or more substituents or a salt thereof or a prodrug thereof, which is useful for the treatment of various diseases.Type: ApplicationFiled: January 27, 2004Publication date: September 7, 2006Inventors: Fumio Itoh, Shuji Hinuma, Naoyuki Kanzaki, Takashi Miki, Yuji Kawamata, Satoru Oi, Taisuke Tawaraishi, Yuji Ishichi, Mariko Hirohashi
-
Publication number: 20050170461Abstract: The present invention relates to the ligand polypeptide for the human pituitary- and mouse pancreas-derived G protein-coupled receptor proteins. The ligand polypeptide or the DNA which codes for the ligand polypeptide can be used for (1) development of medicines such as pituitary function modulators, central nervious system function modulators, and pancreatic function modulators, and (2) development of receptor binding assay systems using the expression of recombinant receptor proteins and screening of pharmaceutical candidate compounds. In particular, by the receptor binding assay systems utilizing the expression of recombinant G protein-coupled receptor proteins in accordance with the invention, agonists and antagonists of G protein-coupled receptors which are specific to human and other warm-blooded animals can be screened and the agonists or antagonists obtained can be used as therapeutic and prophylactic agents for various diseases.Type: ApplicationFiled: February 8, 2005Publication date: August 4, 2005Inventors: Shuji Hinuma, Yugo Habata, Yuji Kawamata, Masaki Hosoya, Ryo Fujii, Shoji Fukusumi, Chieko Kitada
-
Publication number: 20050153289Abstract: The present invention intends to provide a method for analyzing gene expression, a novel use for a receptor protein and the like. Specifically, the present invention provides a method for analyzing gene expression, which is characterized by identifying genes, which are characteristically promoted or suppressed in certain cells or tissues by quantitatively analyzing the individual expressed amounts of a plural number of genes collectively, an assay kit employed in the method and the like. The present invention also provides a method of screening compounds or salts thereof which alter the binding properties of a novel G protein coupled receptor protein comprising an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO: 9 or a salt thereof with a ligand, characterized by the use of the protein or salt thereof and a protein (such as a lectin) showing an affinity for a sugar chain which is one of the ligands.Type: ApplicationFiled: December 13, 2002Publication date: July 14, 2005Inventors: Shuji Hinuma, Makoto Kobayashi, Toshimitsu Arai, Shoji Fukusumi, Ryo Fujii, Hidetoshi Komatsu, Fumika Matsumura, Yuji Kawamata, Kazuhiro Ogi
-
Publication number: 20050118639Abstract: The present invention aims at providing a method of determining a ligand to an orphan receptor. Specifically, the present invention provides a method of determining a ligand to a receptor protein, to which no ligand has been determined, which comprises using a fusion protein of the receptor protein and a fluorescent protein.Type: ApplicationFiled: February 21, 2003Publication date: June 2, 2005Applicant: Takeda Chemical Industries, LtdInventors: Shuji Hinuma, Ryo Fujii, Kazuhiro Ogi, Hidetoshi Komatsu, Yuji Kawamata, Masaki Hosoya
-
Publication number: 20050089866Abstract: By using (1) a G protein-coupled receptor protein having the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or its salt and (2) a fatty acid or an eicosanoid, a compound or its salt that can change the binding properties of the receptor protein or its salt to the fatty acid or the eicosanoid can be screened efficiently.Type: ApplicationFiled: February 13, 2003Publication date: April 28, 2005Inventors: Shuji Hinuma, Masaki Hosoya, Yasuaki Ito, Makoto Kobayashi, Hideyuki Tanaka, Shoichi Ohkubo, Ryo Fujii, Hideki Kizawa, Yuji Kawamata, Kazuhiro Ogi, Masataka Harada, Shoji Fukusumi
-
Patent number: 6881545Abstract: The present invention relates to the ligand polypeptide for the human pituitary- and mouse pancreas-derived G protein-coupled receptor proteins. The ligand polypeptide or the DNA which codes for the ligand polypeptide can be used for (1) development of medicines such as pituitary function modulators, central nervious system function modulators, and pancreatic function modulators, and (2) development of receptor binding assay systems using the expression of recombinant receptor proteins and screening of pharmaceutical candidate compounds. In particular, by the receptor binding assay systems utilizing the expression of recombinant G protein-coupled receptor proteins in accordance with the invention, agonists and antagonists of G protein-coupled receptors which are specific to human and other warm-blooded animals can be screened and the agonists or antagonists obtained can be used as therapeutic and prophylactic agents for various diseases.Type: GrantFiled: November 17, 2000Date of Patent: April 19, 2005Assignee: Takeda Chemical Industries, Ltd.Inventors: Shuji Hinuma, Yugo Habata, Yuji Kawamata, Masaki Hosoya, Ryo Fujii, Shoji Fukusumi, Chieko Kitada
-
Publication number: 20040248208Abstract: Using a G protein-coupled receptor protein (TGR4) or its salt containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, and a phospholipid compound, a compound that alters the binding property between the receptor protein or its salt, and the phospholipids compound, or a salt thereof, can be efficiently screened.Type: ApplicationFiled: February 27, 2004Publication date: December 9, 2004Inventors: Shuji Hinuma, Ryo Fujii, Yugo Habata, Yuji Kawamata, Masaki Hosoya, Shoji Fukusumi, Hidetoshi Komatsu
-
Patent number: 6794491Abstract: The present invention relates to the ligand polypeptide for the human pituitary- and mouse pancreas-derived G protein-coupled receptor proteins. The ligand polypeptide or the DNA which codes for the ligand polypeptide can be used for (1) development of medicines such as pituitary function modulators, central nervious system function modulators, and pancreatic function modulators, and (2) development of receptor binding assay systems using the expression of recombinant receptor proteins and screening of pharmaceutical candidate compounds. In particular, by the receptor binding assay systems utilizing the expression of recombinant G protein-coupled receptor proteins in accordance with the invention, agonists and antagonists of G protein-coupled receptors which are specific to human and other warm-blooded animals can be screened and the agonists or antagonists obtained can be used as therapeutic and prophylactic agents for various diseases.Type: GrantFiled: May 23, 2000Date of Patent: September 21, 2004Assignee: Takeda Chemical Industries, Ltd.Inventors: Shuji Hinuma, Yugo Habata, Yuji Kawamata, Masaki Hosoya, Ryo Fujii, Shoji Fukusumi, Chieko Kitada
-
Publication number: 20040171067Abstract: The present invention intends to provide a screening of agonist/antagonist and the like. Specifically, the invention provides a method of screening a compound or its salt that alters the binding property between a novel G protein-coupled receptor protein or its salt, and a substance relating to cholesterol metabolism, which comprises using the receptor protein or its salt, which contains the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 14 or SEQ ID NO: 16, and the substance relating to cholesterol metabolism.Type: ApplicationFiled: October 8, 2003Publication date: September 2, 2004Inventors: Syuji Hinuma, Ryo Fujii, Yuji Kawamata, Masanori Miwa, Masaki Hosoya
-
Publication number: 20030118586Abstract: Rabbit gastropyrolic part smooth muscle-derived G protein coupled receptor proteins, partial peptides thereof; and DNAs containing said protein or partial peptide-encoding DNA are provided. The receptor protein and the DNA coding for said protein can be used for {circle over (1)} determination of ligands; {circle over (2)} acquisition of antibody and antiserum; {circle over (3)} construction of expression system for of a recombinant type receptor protein; {circle over (4)} development of the receptor binding assay system using said expression system and screening of the candidate compounds for pharmaceuticals; {circle over (5)} conducting a drug design based upon a comparison with structurally analogous ligands and receptors; {circle over (6)} preparation of probes and PCR primers for a gene diagnosis; {circle over (7)} preparation of transgenic animals; and {circle over (8)} preparation of model patient animals deficient in the receptor protein DNA.Type: ApplicationFiled: June 28, 2002Publication date: June 26, 2003Inventors: Shuji Hinuma, Ryo Fujii, Yuji Kawamata
-
Publication number: 20030113909Abstract: Rabbit gastropyrolic part smooth muscle-derived G protein coupled receptor proteins, partial peptides thereof; and DNAs containing said protein or partial peptide-encoding DNA are provided. The receptor protein and the DNA coding for said protein can be used for {circle over (1)} determination of ligands; {circle over (2)} acquisition of antibody and antiserum; {circle over (3)} construction of expression system for of a recombinant type receptor protein; {circle over (4)} development of the receptor binding assay system using said expression system and screening of the candidate compounds for pharmaceuticals; {circle over (5)}conducting a drug design based upon a comparison with structurally analogous ligands and receptors; {circle over (6)} preparation of probes and PCR primers for a gene diagnosis; {circle over (7)} preparation of transgenic animals; and {circle over (8)}preparation of model patient animals deficient in the receptor protein DNA.Type: ApplicationFiled: August 14, 2001Publication date: June 19, 2003Applicant: Takeda Chemical Industries, Ltd.Inventors: Shuji Hinuma, Ryo Fujii, Yuji Kawamata
-
Patent number: 6402013Abstract: A soldering flux suitable for soldering of small electronic components comprises 0.1-50 mass percent of an organic acid, 5-40 mass percent of a solvent, and 10-95 mass percent of a thermosetting resin (including a curing agent), which is preferably a bisphenol A epoxy resin and an acid anhydride or amine curing agent. This flux can be used to prepare a solder paste by mixing with solder powder. This soldering flux can secure an electronic component simultaneously by soldering and by the resin, simply by a soldering operation at a soldering temperature of at least 150° C., and cleaning after soldering is no longer necessary.Type: GrantFiled: December 1, 2000Date of Patent: June 11, 2002Assignees: Senju Metal Industry Co., LTD, TDK CorporationInventors: Hisayuki Abe, Toshihiko Taguchi, Yuji Kawamata, Akiko Iwano
-
Publication number: 20010019075Abstract: A soldering flux suitable for soldering of small electronic components comprises 0.1-50 mass percent of an organic acid, 5-40 mass percent of a solvent, and 10-95 mass percent of a thermosetting resin (including a curing agent), which is preferably a bisphenol A epoxy resin and an acid anhydride or amine curing agent. This flux can be used to prepare a solder paste by mixing with solder powder. This soldering flux can secure an electronic component simultaneously by soldering and by the resin, simply by a soldering operation at a soldering temperature of at least 150° C., and cleaning after soldering is no longer necessary.Type: ApplicationFiled: April 13, 2001Publication date: September 6, 2001Inventors: Hisayuki Abe, Toshihiko Taguchi, Yuji Kawamata, Akiko Iwano
-
Patent number: 6228984Abstract: The present invention relates to the ligand polypeptide for the human pituitary- and mouse pancreas-derived G protein-coupled receptor proteins. The ligand polypeptide or the DNA which codes for the ligand polypeptide can be used for (1) development of medicines such as pituitary function modulators, central nervous system function modulators, and pancreatic function modulators, and (2) development of recombinant receptor proteins and screening of pharmaceutical candidate compounds. In particular, by the receptor binding assay systems utilizing the expression of recombinant G protein-coupled receptor proteins in accordance with the invention, agonists and antagonists of G protein-coupled receptors which are specific to human and other warm-blooded animals can be screened and the agonists or antagonists obtained can be used as therapeutic and prophylactic agents for various diseases.Type: GrantFiled: February 7, 1997Date of Patent: May 8, 2001Assignee: Takeda Chemical Industries, Ltd.Inventors: Shuji Hinuma, Yugo Habata, Yuji Kawamata, Masaki Hosoya, Ryo Fujii, Shoji Fukusumi, Chieko Kitada
-
Patent number: 6048711Abstract: A novel G-protein coupled receptor protein, a partial peptide and their salts are disclosed. DNA encoding the receptor protein, production of the receptor protein, determination of a ligand to the receptor protein, a method for screening for compounds which inhibit ligand binding to the receptor protein, a kit for screening for such compounds are also disclosed. The receptor protein, its partial peptide and their salts are used for screening for candidate compounds of drugs and the like.Type: GrantFiled: October 28, 1997Date of Patent: April 11, 2000Assignee: Takeda Chemical Industries, Ltd.Inventors: Shuji Hinuma, Shoji Fukusumi, Yuji Kawamata
-
Patent number: 5932030Abstract: A flux composition for use together with solder preforms, which comprises rosin, N-unsubstituted or N-substituted 2-pyrrolidone, and optionally a high boiling point ester solvent with a content of N-unsubstituted or N-substituted 2-pyrrolidone being 3-50% by weight and a content of the ester solvent being not greater than 30% by weight.Type: GrantFiled: April 30, 1996Date of Patent: August 3, 1999Assignees: Sony Corporation, Senju Metal Industry Co., Ltd.Inventors: Hiroyuki Fukasawa, Yuji Kawamata